Cencora, Inc. saw its stock plummet 17.3% after reporting Q2 earnings that missed estimates by $0.07, coming in at an adjusted EPS of $4.75. The company further trimmed its revenue growth forecast in light of slower U.S. sales, prompting Rosen Law Firm to initiate an investigation into potential misleading business information. Despite reporting $78.4 billion in revenue and recent strategic acquisitions, these developments have shaken investor confidence and increased trading volatility.
“Cencora · reported · 6% adjusted operating income growth and 7.5% adjusted EPS growth · true”
“Cencora · is a · company · true”
“Cencora · formerly known as · AmerisourceBergen”
“Cencora · is a · global healthcare solutions leader”
“Rosen Law Firm · announces an investigation of · Cencora, Inc. investors · potential securities claims on behalf of shareholders resulting from allegations that Cencora may have issued materially misleading business information”
“Cencora, Inc. · stock fell · 17.3% · on May 6, 2026”
“Cencora · reported · Q2 results · adjusted EPS of $4.75”
“Cencora · reported · revenue · $78.4 billion”
“Cencora · raised · fiscal 2026 adjusted EPS guidance”
“Cencora · trimmed · revenue growth forecasts”
“Cencora · was founded · in 1871”
“Cencora · changed its name · to Cencora, Inc. · in August 2023”